WO2012093973A2 - Stable acarbose formulations - Google Patents

Stable acarbose formulations Download PDF

Info

Publication number
WO2012093973A2
WO2012093973A2 PCT/TR2012/000004 TR2012000004W WO2012093973A2 WO 2012093973 A2 WO2012093973 A2 WO 2012093973A2 TR 2012000004 W TR2012000004 W TR 2012000004W WO 2012093973 A2 WO2012093973 A2 WO 2012093973A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
range
acarbose
comprised
formulation according
Prior art date
Application number
PCT/TR2012/000004
Other languages
French (fr)
Other versions
WO2012093973A3 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012093973A2 publication Critical patent/WO2012093973A2/en
Publication of WO2012093973A3 publication Critical patent/WO2012093973A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to formulations comprising acarbose and use of these formulations in diabetes, adiposity and hyperlipoidemia.
  • Diabetes is a chronic disease which is characterized by insufficient or lack of insulin production by the pancreas and leads to disorders of carbohydrate, lipid and protein metabolism. There are two major types of diabetes.
  • Type I diabetes grows because beta cells in the pancreas can produce very little or no insulin associated with autoimmune mechanisms. Insulin is a hormone which is responsible for reducing elevated blood sugar. Blood sugar level rises depending on reduction in amount or in efficiency of insulin (hyperglycemia). Type I diabetes generally develops in children or young adults. Type II diabetes is the most common type of diabetes and characterized by insulin resistance. In this type of diabetes, insulin is released properly but it cannot be sufficiently effective. In some cases, the amount of insulin can be too much.
  • the primary treatment method is diet and exercise for diabetic patients. This treatment approach provides very little weight loss but regulates insulin sensitivity. Sometimes, it can be possible to control blood sugar level for a long time only with this treatment method. However, the tendency towards insulin resistance in these people never disappears; therefore, diet, exercise and weight control should be maintained continuously. In the cases that diet and exercise are insufficient, the second step of the treatment is oral anti-diabetic drugs and insulin reinforcement.
  • the main oral anti-diabetics are sulfonylureas, biguanides and alpha glucosidase inhibitors.
  • Acarbose which is an alpha glucosidase inhibitor was first disclosed in the patent document numbered DE2347782.
  • Acarbose ? (formula I), chemical name of which is 0- ⁇ 4-Amino-4,6- dideoxy-N-((lS,4R,5S-,6S)-4,5,6-trihydroxy-3-hydroxymethylcyclohex-2-enyl)-alpha-D- glucopyranosyl ⁇ -(l->4)-0-alpha-D-glucopyranosyl-(l->4)-D-glucopyranose (formula I) is an alpha glucosidase inhibitor.
  • Acarbose is produced by fermentation of the microorganism called Actinoplanes utahensis.
  • Acarbose inhibits alpha glucosidase enzyme which is responsible for digestion of carbohydrates in lumen of the small intestine. Digestion and absorption of carbohydrates in the intestine are slowed down by inhibition of this enzyme; therefore elevation in blood sugar level after meals is prevented. Acarbose does not affect insulin release from the pancreas, insulin use in the tissues or glucose outflow from the liver. Therefore, acarbose does not cause hypoglycaemia when used singly.
  • acarbose can be preferred as primary treatment in the case that there is diabetes that cannot be controlled by diet or it can be preferred as a combination treatment option in the case that postprandial hyperglycemias cannot be prevented during treatments of sulfonurea, biguanide or insulin.
  • Acarbose is a highly hygroscopic substance.
  • acarbose which has more than 6% of water content disintegrates at 60°C in 6 weeks.
  • increase in weight, decrease in hardness and changes in appearance (white tablets turn into light yellow and light brown) of acarbose tablets occur after keeping them at 20 °C under 75% of moisture or at 30 °C under 90% of moisture for 4 weeks.
  • the pharmaceutical formulations comprising acarbose tend to degrade easily due to its hygroscopic characteristic depending on production and storage conditions. Dry blending method is usually preferred in production phase due to hygroscopic characteristic of the active agent acarbose.
  • acarbose formulations produced by this method are compressed into tablets, it has been seen that the tablet formulations prepared cannot have sufficient hardness and therefore, the formulations prepared disintegrate in blisters during storage and carrying phases.
  • the inventors have unexpectedly found that sufficient tablet hardness property can be provided in the tablet formulations prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25%. This surprising effect is achieved by using microcrystalline cellulose in the range of 20-25% in the formulations of the present invention.
  • the present invention relates to the tablet formulation prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25% by weight in addition to the active agent acarbose.
  • acarbose formulations in tablet form prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25%) by weight maintain stability both during and after production phase, and the tablet formulations produced have sufficient tablet hardness.
  • microcrystalline cellulose in the range of 20-25%) by weight in acarbose compositions in tablet form prepared by dry blending method enables that stability of said formulations increases and furthermore the tablets having sufficient hardness are produced.
  • the amount of the active agent acarbose used in the formulation of the present invention is in the range of 10-500 mg, preferably in the range of 20-200 mg, more preferably in the range of 50-100 mg.
  • the active agent acarbose used in the formulation of the present invention is in the range of 10-50% by weight, preferably in the range of 30-40%) by weight.
  • acarbose tablet formulations of the present invention prepared by dry blending method is that the formulations comprise acarbose in the range of 30 to 40% by weight.
  • Acarbose tablet formulations of the present invention prepared by dry blending method can optionally comprise one or more of the excipients including binder, lubricant, glidant, diluent, disintegrant, surfactant, stabilizing agent, humectant.
  • the binder mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatine; cellulose derivatives such as HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol; water or a combination thereof.
  • starches such as potato starch, corn starch, wheat starch
  • sugars such as sucrose, glucose, dextrose, lactose, maltodextrin
  • natural and synthetic gums gelatine
  • cellulose derivatives such as HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose
  • the binder used in the formulation of the present invention is starch, preferably corn starch.
  • the amount of corn starch comprised in the formulation of the present invention is in the range of 30-50 % by weight.
  • microcrystalline cellulose:corn starch ratio comprised in the formulations is in the range of 1 : 1.5 to 1 :2.
  • the lubricant mentioned herein can be selected from sodium lauryl sulphate, calcium stearate, magnesium stearate, polyethylene glycol, polyvinyl alcohol, potassium benzoate, sodium benzoate, sodium chloride, carbowax 4000, talc or a combination thereof.
  • the type and amount of the lubricant comprised in the formulations have been selected carefully in order to provide sufficient tablet hardness property of acarbose formulations of the present invention.
  • the lubricant used in the formulation of the present invention is preferably magnesium stearate.
  • the amount of magnesium stearate comprised in the formulation of the present invention is in the range of 0.1-2% by weight.
  • Another characteristic feature of acarbose tablet formulations of the present invention prepared by dry blending method is that the formulations comprise magnesium stearate in the range of 0.1-2% by weight as lubricant.
  • acarbose formulations of the present invention can comprise at least one pharmaceutically acceptable glidant in addition to lubricant.
  • the glidant mentioned herein can be selected from talc, magnesium stearate, stearic acid, sodium stearyl fumarate, polyoxyethylene glycol, leucine, alanine, glycine, sodium benzoate, sodium acetate, fumaric acid, silicone dioxide or a combination thereof.
  • the formulations comprise at least one glidant in addition to lubricant, it is preferred that the ratio of lubricant to glidant is at least 1.
  • the diluent mentioned herein can be selected from lactose, maltose, dextrin, maltodextrin, mannitol, sorbitol, starch, calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, magnesium carbonate, magnesium oxide or a combination thereof.
  • the disintegrant mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch, pregelatinized starch, sodium starch glycolate; cellulose derivatives such as croscarmellose sodium or microcrystalline cellulose; polyvinylpyrrolidone; crospovidone; alginic acid and its salts; chyles such as xanthan gum or veegum; ion-exchange resins or a combination thereof.
  • the surfactant mentioned herein can be selected from sodium lauryl sulphate and magnesium lauryl sulphate or a combination thereof.
  • the stabilizing agent and/or agents mentioned herein can be selected from antioxidants, chelating agents, alkalinizing agents and photo-protectives.
  • the antioxidants can be selected from the substances such as butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulphide, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • gallates such as propyl gallate
  • tocopherol citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • the chelating agents can be selected from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate of a combination thereof.
  • the alkalinizing agents can be selected from alkaline metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; earth alkaline metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium gliserophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate and organic compounds such as primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '- dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium al
  • the photo-protective agents can be selected from metal oxides such as titanium oxide, iron oxide or zinc oxide or a combination thereof.
  • the humectant mentioned herein can be selected from anhydrous sodium sulphate, silica gel and potassium carbonate or a combination thereof.
  • the formulation of the present invention can be used in treatment of diabetes, adiposity and hyperlipidemia.
  • the formulation of the present invention can be used in combination with other drugs used in treatment of diabetes such as acetohexamide, carbutamide, chlorpropamide, gliclazide, tolbutamide, tolazamide, glibenclamide, glipizide, gliquidone, glycol pyramide, glimepiride, metformine, buformin, phenformin, thiazolidinedione pioglitazone, rivoglitazone, troglitazone, meglitinide, insulin.
  • drugs used in treatment of diabetes such as acetohexamide, carbutamide, chlorpropamide, gliclazide, tolbutamide, tolazamide, glibenclamide, glipizide, gliquidone, glycol pyramide, glimepiride, metformine, buformin, phenformin, thiazolidinedione pioglitazone, rivoglitazone, troglitazone, meglitinide, insulin.
  • compositions used within the scope of the present invention are pharmaceutically suitable.
  • pharmaceutically suitable signifies that the component used is suitable for human use, has a few or no unexpected side effects (toxicity, irritations, allergic response) and provides a significant benefit to user.
  • Acarbose, microcrystalline cellulose, corn starch and the other excipients are mixed in a container mixer. After magnesium stearate is added into the mixture obtained and mixed in the container mixture, compression process is performed by loading the mixture to tablet compression machine.

Abstract

The present invention relates to the formulations comprising acarbose and use of these formulations in diabetes, adiposity and hyperlipoidemia.

Description

STABLE ACARBOSE FORMULATIONS
The Prior Art
The present invention relates to formulations comprising acarbose and use of these formulations in diabetes, adiposity and hyperlipoidemia.
The Prior Art
Diabetes is a chronic disease which is characterized by insufficient or lack of insulin production by the pancreas and leads to disorders of carbohydrate, lipid and protein metabolism. There are two major types of diabetes.
Type I diabetes grows because beta cells in the pancreas can produce very little or no insulin associated with autoimmune mechanisms. Insulin is a hormone which is responsible for reducing elevated blood sugar. Blood sugar level rises depending on reduction in amount or in efficiency of insulin (hyperglycemia). Type I diabetes generally develops in children or young adults. Type II diabetes is the most common type of diabetes and characterized by insulin resistance. In this type of diabetes, insulin is released properly but it cannot be sufficiently effective. In some cases, the amount of insulin can be too much.
In treatment of diabetes, it is aimed to reduce symptoms, improve life quality, prevent acute and chronic symptoms. The primary treatment method is diet and exercise for diabetic patients. This treatment approach provides very little weight loss but regulates insulin sensitivity. Sometimes, it can be possible to control blood sugar level for a long time only with this treatment method. However, the tendency towards insulin resistance in these people never disappears; therefore, diet, exercise and weight control should be maintained continuously. In the cases that diet and exercise are insufficient, the second step of the treatment is oral anti-diabetic drugs and insulin reinforcement. The main oral anti-diabetics are sulfonylureas, biguanides and alpha glucosidase inhibitors.
Acarbose which is an alpha glucosidase inhibitor was first disclosed in the patent document numbered DE2347782. Acarbose? (formula I), chemical name of which is 0-{4-Amino-4,6- dideoxy-N-((lS,4R,5S-,6S)-4,5,6-trihydroxy-3-hydroxymethylcyclohex-2-enyl)-alpha-D- glucopyranosyl }-(l->4)-0-alpha-D-glucopyranosyl-(l->4)-D-glucopyranose (formula I) is an alpha glucosidase inhibitor. Acarbose is produced by fermentation of the microorganism called Actinoplanes utahensis.
Figure imgf000003_0001
(Formula 1)
Acarbose inhibits alpha glucosidase enzyme which is responsible for digestion of carbohydrates in lumen of the small intestine. Digestion and absorption of carbohydrates in the intestine are slowed down by inhibition of this enzyme; therefore elevation in blood sugar level after meals is prevented. Acarbose does not affect insulin release from the pancreas, insulin use in the tissues or glucose outflow from the liver. Therefore, acarbose does not cause hypoglycaemia when used singly. Use of acarbose can be preferred as primary treatment in the case that there is diabetes that cannot be controlled by diet or it can be preferred as a combination treatment option in the case that postprandial hyperglycemias cannot be prevented during treatments of sulfonurea, biguanide or insulin.
Acarbose is a highly hygroscopic substance. For instance, according to the Japanese Patent Publication No. 39340/1995, acarbose which has more than 6% of water content disintegrates at 60°C in 6 weeks. Furthermore, another study has showed that increase in weight, decrease in hardness and changes in appearance (white tablets turn into light yellow and light brown) of acarbose tablets occur after keeping them at 20 °C under 75% of moisture or at 30 °C under 90% of moisture for 4 weeks. (Igaku to Yakugaku, Medical Science And Pharmacy, Vol. 32, No. 3, p. 597-601, 1994).
The pharmaceutical formulations comprising acarbose tend to degrade easily due to its hygroscopic characteristic depending on production and storage conditions. Dry blending method is usually preferred in production phase due to hygroscopic characteristic of the active agent acarbose. However, in the case that acarbose formulations produced by this method are compressed into tablets, it has been seen that the tablet formulations prepared cannot have sufficient hardness and therefore, the formulations prepared disintegrate in blisters during storage and carrying phases.
However, the inventors have unexpectedly found that sufficient tablet hardness property can be provided in the tablet formulations prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25%. This surprising effect is achieved by using microcrystalline cellulose in the range of 20-25% in the formulations of the present invention.
Detailed Description of the Invention
In this aspect, the present invention relates to the tablet formulation prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25% by weight in addition to the active agent acarbose.
The inventors have observed that acarbose formulations in tablet form prepared by dry blending method and comprising microcrystalline cellulose in the range of 20-25%) by weight maintain stability both during and after production phase, and the tablet formulations produced have sufficient tablet hardness.
In other words, use of microcrystalline cellulose in the range of 20-25%) by weight in acarbose compositions in tablet form prepared by dry blending method enables that stability of said formulations increases and furthermore the tablets having sufficient hardness are produced.
The amount of the active agent acarbose used in the formulation of the present invention is in the range of 10-500 mg, preferably in the range of 20-200 mg, more preferably in the range of 50-100 mg.
The active agent acarbose used in the formulation of the present invention is in the range of 10-50% by weight, preferably in the range of 30-40%) by weight.
Comprising more than 40% of active agent in the formulations is not preferred since it shall change the amount of microcrystalline cellulose comprised in the formulations and it causes that stability and tablet hardness properties cannot be provided. Less than 30%> of active agent, on the other hand, cannot provide sufficient therapeutic benefit. One characteristic feature of acarbose tablet formulations of the present invention prepared by dry blending method is that the formulations comprise acarbose in the range of 30 to 40% by weight.
Acarbose tablet formulations of the present invention prepared by dry blending method can optionally comprise one or more of the excipients including binder, lubricant, glidant, diluent, disintegrant, surfactant, stabilizing agent, humectant.
The binder mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatine; cellulose derivatives such as HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol; water or a combination thereof.
The binder used in the formulation of the present invention is starch, preferably corn starch.
The amount of corn starch comprised in the formulation of the present invention is in the range of 30-50 % by weight.
Another characteristic feature of acarbose tablet formulations of the present invention prepared by dry blending method is that microcrystalline cellulose:corn starch ratio comprised in the formulations is in the range of 1 : 1.5 to 1 :2.
The lubricant mentioned herein can be selected from sodium lauryl sulphate, calcium stearate, magnesium stearate, polyethylene glycol, polyvinyl alcohol, potassium benzoate, sodium benzoate, sodium chloride, carbowax 4000, talc or a combination thereof.
The type and amount of the lubricant comprised in the formulations have been selected carefully in order to provide sufficient tablet hardness property of acarbose formulations of the present invention.
The lubricant used in the formulation of the present invention is preferably magnesium stearate.
The amount of magnesium stearate comprised in the formulation of the present invention is in the range of 0.1-2% by weight. Another characteristic feature of acarbose tablet formulations of the present invention prepared by dry blending method is that the formulations comprise magnesium stearate in the range of 0.1-2% by weight as lubricant.
In other aspect, acarbose formulations of the present invention can comprise at least one pharmaceutically acceptable glidant in addition to lubricant. The glidant mentioned herein can be selected from talc, magnesium stearate, stearic acid, sodium stearyl fumarate, polyoxyethylene glycol, leucine, alanine, glycine, sodium benzoate, sodium acetate, fumaric acid, silicone dioxide or a combination thereof. In the case that the formulations comprise at least one glidant in addition to lubricant, it is preferred that the ratio of lubricant to glidant is at least 1.
The diluent mentioned herein can be selected from lactose, maltose, dextrin, maltodextrin, mannitol, sorbitol, starch, calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, magnesium carbonate, magnesium oxide or a combination thereof.
The disintegrant mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch, pregelatinized starch, sodium starch glycolate; cellulose derivatives such as croscarmellose sodium or microcrystalline cellulose; polyvinylpyrrolidone; crospovidone; alginic acid and its salts; chyles such as xanthan gum or veegum; ion-exchange resins or a combination thereof.
The surfactant mentioned herein can be selected from sodium lauryl sulphate and magnesium lauryl sulphate or a combination thereof.
The stabilizing agent and/or agents mentioned herein can be selected from antioxidants, chelating agents, alkalinizing agents and photo-protectives.
The antioxidants can be selected from the substances such as butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulphide, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
The chelating agents can be selected from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate of a combination thereof. The alkalinizing agents can be selected from alkaline metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; earth alkaline metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium gliserophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate and organic compounds such as primary, secondary and tertiary amines, cyclic amines, Ν,Ν'- dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate or a combination thereof.
The photo-protective agents can be selected from metal oxides such as titanium oxide, iron oxide or zinc oxide or a combination thereof.
The humectant mentioned herein can be selected from anhydrous sodium sulphate, silica gel and potassium carbonate or a combination thereof.
One characteristic feature of acarbose tablet formulations of the present invention prepared by dry blending method is that the formulations comprise
- acarbose in the range of 10-50% by weight
- macrocrystalline cellulose in the range of 20-25% by weight
- corn starch in the range of 30-50% by weight
- magnesium stearate in the range of 0.1 -2% by weight and
- optionally the other excipients in the range of 0-30% by weight.
A process in order to prepare the formulation of the present invention characterized in that the formulation is composed of the steps of:
- Blending acarbose, microcrystalline cellulose and corn starch dryly
- Mixing the blend by adding magnesium stearate
- Compressing tablets.
The formulation of the present invention can be used in treatment of diabetes, adiposity and hyperlipidemia.
The formulation of the present invention can be used in combination with other drugs used in treatment of diabetes such as acetohexamide, carbutamide, chlorpropamide, gliclazide, tolbutamide, tolazamide, glibenclamide, glipizide, gliquidone, glycol pyramide, glimepiride, metformine, buformin, phenformin, thiazolidinedione pioglitazone, rivoglitazone, troglitazone, meglitinide, insulin.
All of the components used within the scope of the present invention are pharmaceutically suitable. The term pharmaceutically suitable signifies that the component used is suitable for human use, has a few or no unexpected side effects (toxicity, irritations, allergic response) and provides a significant benefit to user.
The examples below are given in order to explain the invention. The scope of the invention is not limited to these examples and these examples are evaluated with the description above which is described in detail.
Example 1
Acarbose, microcrystalline cellulose, corn starch and the other excipients are mixed in a container mixer. After magnesium stearate is added into the mixture obtained and mixed in the container mixture, compression process is performed by loading the mixture to tablet compression machine.
Example 2
Figure imgf000009_0001

Claims

1. A tablet formulation comprising acarbose and prepared by dry blending method characterized in that the formulation comprises microcrystalline cellulose in the range of 20-25% by weight.
2. The formulation according to claim 1 characterized in that the formulation comprises acarbose in the range of 10 to 50 % by weight.
3. The formulation according to claim 2 characterized in that the formulation comprises acarbose in the range of 10 to 40% by weight.
4. The formulation according to any preceding claims characterized in that the formulations comprise one or more of the excipients comprising binder, lubricant, glidant, diluent, disintegrant, surfactant, stabilizing agent, humectant.
5. The formulation according to claim 4 characterized in that the binder comprised in the formulation is selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatine; cellulose derivatives such as HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol; water or a combination thereof.
6. The formulation according to claim 5 characterized in that the binder comprised in the formulation is starch.
7. The formulation according to claim 6 characterized in that the binder comprised in the formulation is corn starch.
8. The formulation according to claims 6-7 characterized in that the amount of corn starch comprised in the formulation is in the range of 30-50 % by weight.
9. The formulation according to claims 7-8 characterized in that microcrystalline cellulosexorn starch ratio comprised in the formulation is in the range of 1 : 1.5 to 1 :2.
10. The formulation according to claim 4 characterized in that the lubricant comprised in the formulation is selected from a group comprising sodium lauryl sulphate, calcium stearate, magnesium stearate, polyethylene glycol, polyvinyl alcohol, potassium benzoate, sodium benzoate, sodium chloride, carbowax 4000, talc or a combination thereof.
11. The formulation according to claim 10 characterized in that the lubricant comprised in the formulation is magnesium stearate.
2. The formulation according to claim 11 characterized in that the amount of magnesium stearate comprised in the formulation is in the range of 0.1-2% by weight.
PCT/TR2012/000004 2011-01-06 2012-01-06 Stable acarbose formulations WO2012093973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00148A TR201100148A2 (en) 2011-01-06 2011-01-06 Stable acarbose formulations.
TR2011/00148 2011-01-06

Publications (2)

Publication Number Publication Date
WO2012093973A2 true WO2012093973A2 (en) 2012-07-12
WO2012093973A3 WO2012093973A3 (en) 2012-10-18

Family

ID=45879005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000004 WO2012093973A2 (en) 2011-01-06 2012-01-06 Stable acarbose formulations

Country Status (2)

Country Link
TR (1) TR201100148A2 (en)
WO (1) WO2012093973A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN104971080A (en) * 2015-06-09 2015-10-14 中国科学院西北高原生物研究所 Use of Berberis dasystachya Maxim. fruit polysaccharide in dyslipidemia improvement
CN104983771A (en) * 2015-06-09 2015-10-21 中国科学院西北高原生物研究所 Application of yellow thorn fruits to treating dyslipidemia
CN114053234A (en) * 2021-12-29 2022-02-18 江苏省药物研究所有限公司 Acarbose tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2347782A1 (en) 1973-09-22 1975-04-10 Bayer Ag AMINO SUGAR DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
JPH0739340A (en) 1993-08-04 1995-02-10 Shozo Shimizu Method for preventing discoloration of foliage of japanese horseradish due to high-temperature heat sterilization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (en) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen NEW MEDICINE PREPARATIONS FOR GLYCOSIDE HYDROLASE INHIBITORS
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
FR2834214B1 (en) * 2001-12-28 2004-09-24 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND 4-OXO-BUTANOIC ACID AND ITS USE FOR TREATING DIABETES
CN100464754C (en) * 2007-03-12 2009-03-04 杭州中美华东制药有限公司 Acarbose medicine composition and its prepn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2347782A1 (en) 1973-09-22 1975-04-10 Bayer Ag AMINO SUGAR DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT
JPH0739340A (en) 1993-08-04 1995-02-10 Shozo Shimizu Method for preventing discoloration of foliage of japanese horseradish due to high-temperature heat sterilization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IGAKU TO YAKUGAKU, vol. 32, no. 3, 1994, pages 597 - 601

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
EP2890370A4 (en) * 2012-08-31 2016-09-28 Univ California Agents useful for treating obesity, diabetes and related disorders
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN104971080A (en) * 2015-06-09 2015-10-14 中国科学院西北高原生物研究所 Use of Berberis dasystachya Maxim. fruit polysaccharide in dyslipidemia improvement
CN104983771A (en) * 2015-06-09 2015-10-21 中国科学院西北高原生物研究所 Application of yellow thorn fruits to treating dyslipidemia
CN104971080B (en) * 2015-06-09 2018-12-28 中国科学院西北高原生物研究所 Yellow bur reality polysaccharide improves the purposes of disorders of lipid metabolism
CN104983771B (en) * 2015-06-09 2018-12-28 中国科学院西北高原生物研究所 Yellow bur improves the purposes of disorders of lipid metabolism in fact
CN114053234A (en) * 2021-12-29 2022-02-18 江苏省药物研究所有限公司 Acarbose tablet and preparation method thereof

Also Published As

Publication number Publication date
WO2012093973A3 (en) 2012-10-18
TR201100148A2 (en) 2012-07-23

Similar Documents

Publication Publication Date Title
JP6066144B2 (en) Concomitant medication
US20080031940A1 (en) Quercetin-containing composition, methods of making, and methods of using
TW200838548A (en) Pharmaceutical composition comprising a pyrazole-O-glucoside derivative
KR101272470B1 (en) Immediate-release and sustained-release pharmaceutical composition comprising levodropropizine
EP2903602B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2021086292A1 (en) Bilayer tablet formulations comprising dapagliflozin and metformin
WO2012093973A2 (en) Stable acarbose formulations
EP3781135A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
WO2012093972A1 (en) Water soluble dosage forms
CN101181264A (en) Pharmaceutical composition taking metformin hydrochloride and vigelegting as active component as well as preparing method and uses thereof
EP4025194A1 (en) A combination comprising vildagliptin and metformin
KR20050016935A (en) Drug composition for blood sugar control
CN102481254A (en) Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes
BR112020017056A2 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING REMOGLIFLOZINE AND AN ANTIDIABETIC AGENT
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
WO2013095316A1 (en) Synergic combination comprising anti-diabetic agent
US20210093698A1 (en) Treatment of type 2 diabetes mellitus
CN114712488B (en) Pharmaceutical compositions of dorzagliptin and glucagon-like peptide-1 analogs
EP2809316A1 (en) Synergisctic combination comprising a meglitinide derivative and lipoic acid
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
KR100657785B1 (en) A medical agent containing glimepiride, metformin and ginkgo biloba extract
WO2021053564A1 (en) Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
CN1704048A (en) Compound calcium phenolsulfonic acid
RU2465896C2 (en) Pharmaceutical anti-diabetic composition of prolonged action
WO2022119540A2 (en) A process for formulations of dapagliflozin and metformin hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710576

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12710576

Country of ref document: EP

Kind code of ref document: A2